Post-Hoc Analysis of Phase 3 Study Examines Effect of Early Intervention with Edaravone on Survival and Disease Progression Milestone Events in ALS Patients prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Mitsubishi Tanabe Pharma America Celebrates Five Years of Dedication to the ALS Community in the U.S.
February 8, 2021 GMT
MTPA Logo (PRNewsfoto/Mitsubishi Tanabe Pharma Americ)
JERSEY CITY, N.J., Feb. 8, 2021 /PRNewswire/ Mitsubishi Tanabe Pharma America, Inc. (MTPA) today celebrated its five-year anniversary of being established in the United States in 2016. MTPA has followed an unwavering patient-first philosophy focused on advancing innovative treatments for people facing serious and life-threatening diseases, including amyotrophic lateral sclerosis (ALS).
“Having personally been a part of the MTPA journey from the beginning, I am humbled by what we have achieved as one team, with one mission: helping patients,” said Atsushi Fujimoto, President, MTPA. “We have accomplished many things in the first five years working together to serve the ALS community, and we look forward to s
Supply deal commercializes oral film formulation of riluzole for ALS
Source/Disclosures ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Back to Healio
Mitsubishi Tanabe Pharma America and Aquestive Therapeutics announced a licensing and supply deal for U.S. rights to commercialize an oral film formulation of riluzole for the treatment of ALS, according to a press release.
Search jobs Mitsubishi Tanabe Pharma America Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS
JERSEY CITY, N.J., Dec. 22, 2020 /PRNewswire/ Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase 3 trial evaluating an investigational oral formulation of edaravone in patients with amyotrophic lateral sclerosis (ALS). The studies are sponsored by Mitsubishi Tanabe Pharma Development America, Inc. (MTDA). As a company, we strive to always put patients first in our efforts to understand this debilitating disease, said Atsushi Fujimoto, President, MTPA. We hope this extension study will help provide important information to the ALS community.